Business
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect
IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers. \n \n \n \n \n \n \n \nCaris and Everlywell are partnering to launch Caris Detect™, Caris' forthcoming Multi-Cancer Early Detection (MCED) blood-based screening assay, through Everlywell's platform. Caris Detect utilizes comprehensive whole genome sequencing (WGS) technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream.\"Caris Life Sciences is proud to partner with Everlywell to expand access to Caris Detect, Caris' revolutionary MCED assay driven by WGS technology,\" said Caris President David Spetzler, MS, PhD, MBA. \"By combining our advanced precision medicine technologies with Everlywell's consumer-focused platform, we're creating a powerful new pathway for people to detect cancer at its earliest and most treatable stages, before it can spread, ultimately supporting better outcomes for patients.\"\"Our partnership with Caris Life Sciences will enhance access to Caris Detect testing, which represents a powerful step forward in how cancer is identified earlier and more proactively,\" said Julia Cheek, Founder and CEO, Everlywell. \"Everlywell has spent the last decade defining the standard for accessible diagnostics. By combining our consumer reach, established infrastructure, and clinical leadership, we are uniquely positioned to bring this transformational technology to people across the country.\"Caris expects to launch the Caris Detect assay in the first half of 2026.About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability need...